Hodges Capital Management Inc. Supernus Pharmaceuticals, Inc. Transaction History

Hodges Capital Management Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Oct 29, 2018	SELL	$42.7 - $56.55 $9.34 Million - $12.4 Million	-218,625 Closed	0 $0
Q2 2018 Jul 26, 2018	SELL	$44.1 - $59.85 $2.52 Million - $3.41 Million	-57,050 Reduced 20.69%	218,625 $13.1 Million
Q1 2018 May 03, 2018	SELL	$37.15 - $46.9 $1.05 Million - $1.33 Million	-28,320 Reduced 9.32%	275,675 $12.6 Million
Q4 2017 Feb 06, 2018	SELL	$36.4 - $42.6 $908,180 - $1.06 Million	-24,950 Reduced 7.58%	303,995 $12.1 Million
Q3 2017 Nov 02, 2017	BUY	$36.75 - $49.65 $12.1 Million - $16.3 Million	328,945	328,945 $13.2 Million

281

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.9B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Hodges Capital Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hodges Capital Management Inc. with notifications on news.